ViroPharma Announces Start of HCV-796 Phase I Program

ViroPharma has announced that dosing has begun in the Phase I clinical trial for HCV-796, a novel polymerase inhibitor being developed as a potential new product to treat hepatitis C.

ViroPharma is conducting this Phase I clinical trial with its partner in the development of antiviral compounds targeting hepatitis C (HCV), Wyeth Pharmaceuticals, a division of Wyeth. Preclinical studies have shown that HCV-796 may be more potent than other anti-HCV compounds developed to date between the two companies.